• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

社区肝病识别与分层委托路径的制定与实施

The Development and Implementation of a Commissioned Pathway for the Identification and Stratification of Liver Disease in the Community.

作者信息

Chalmers J, Wilkes E, Harris R, Kent L, Kinra S, Aithal G P, Holmes M, Johnson J, Morling J R, Guha I N

机构信息

NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, UK.

Nottingham Digestive Diseases Centre, Nottingham, UK.

出版信息

Frontline Gastroenterol. 2020 Feb 10;11(2):86-92. doi: 10.1136/flgastro-2019-101177. Epub 2019 Jun 26.

DOI:10.1136/flgastro-2019-101177
PMID:32066993
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7025872/
Abstract

OBJECTIVE

To describe the development of the Nottingham liver disease stratification pathway, present a 12-month evaluation of uptake, stratification results and compare the pathway to current British Society of Gastroenterology (BSG) guidelines.

DESIGN

A referral pathway between primary and secondary care for the detection and risk stratification of liver disease.

SETTING

Four Nottinghamshire Clinical Commissioning Groups (700,000 population).

PATIENTS

Patients are referred to the pathway with i) raised AST/ALT ratio ii) harmful alcohol use or iii) risk or presence of non-alcoholic fatty liver disease (NAFLD).

INTERVENTIONS

Clinic attendance within secondary care for transient elastography (TE) and brief lifestyle intervention. The TE result is reported back to the GP with advice on interpretation and referral guidance.

MAIN OUTCOME MEASURES

Pathway uptake, patient characteristics, liver disease stratification results and stakeholder feedback.

RESULTS

Over the first 12 months 968 patients attended a TE clinic appointment, with raised AST/ALT ratio being the most common single reason for referral (36.9%). Of the total, 222 (22.9%) patients had an elevated liver stiffness (≥8kPa) and in 60 (27.0%) liver stiffness was indicative of advanced chronic liver disease. If a traditional approach based on raised liver enzymes (BSG guidance) had been followed, 38.7% of those with significant liver disease (≥8kPa) would have gone undetected among those referred for either NAFLD or raised AST:ALT.

CONCLUSIONS

Targeting patients with risk factors for chronic liver disease and stratifying them using TE can detect significant chronic liver disease above and beyond the approach based on liver enzyme elevation.

摘要

目的

描述诺丁汉肝病分层路径的发展情况,呈现对其应用情况、分层结果的12个月评估,并将该路径与英国胃肠病学会(BSG)现行指南进行比较。

设计

初级和二级医疗保健机构之间用于肝病检测和风险分层的转诊路径。

地点

四个诺丁汉郡临床委托小组(70万人口)。

患者

因以下情况被转诊至该路径的患者:i)AST/ALT比值升高;ii)有害饮酒;iii)非酒精性脂肪性肝病(NAFLD)风险或存在NAFLD。

干预措施

在二级医疗保健机构就诊进行瞬时弹性成像(TE)检查和简短的生活方式干预。TE结果会反馈给全科医生,并提供解读建议和转诊指导。

主要观察指标

路径应用情况、患者特征、肝病分层结果及利益相关者反馈。

结果

在最初的12个月里,968名患者参加了TE门诊预约,AST/ALT比值升高是最常见的单一转诊原因(36.9%)。其中,222名(22.9%)患者肝脏硬度升高(≥8kPa),60名(27.0%)患者的肝脏硬度表明存在晚期慢性肝病。如果遵循基于肝酶升高的传统方法(BSG指南),在因NAFLD或AST:ALT升高而转诊的患者中,38.7%患有严重肝病(≥8kPa)的患者将无法被检测出来。

结论

针对有慢性肝病风险因素的患者,并使用TE对其进行分层,能够检测出基于肝酶升高方法之外的严重慢性肝病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/503e/7043077/634f6c8bcb1f/flgastro-2019-101177f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/503e/7043077/2cc9141b682d/flgastro-2019-101177f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/503e/7043077/3ef78d733910/flgastro-2019-101177f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/503e/7043077/634f6c8bcb1f/flgastro-2019-101177f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/503e/7043077/2cc9141b682d/flgastro-2019-101177f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/503e/7043077/3ef78d733910/flgastro-2019-101177f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/503e/7043077/634f6c8bcb1f/flgastro-2019-101177f03.jpg

相似文献

1
The Development and Implementation of a Commissioned Pathway for the Identification and Stratification of Liver Disease in the Community.社区肝病识别与分层委托路径的制定与实施
Frontline Gastroenterol. 2020 Feb 10;11(2):86-92. doi: 10.1136/flgastro-2019-101177. Epub 2019 Jun 26.
2
Embedding assessment of liver fibrosis into routine diabetic review in primary care.将肝纤维化评估纳入基层医疗中糖尿病常规复诊流程。
JHEP Rep. 2021 Apr 22;3(4):100293. doi: 10.1016/j.jhepr.2021.100293. eCollection 2021 Aug.
3
Retrospective analysis of a dedicated care pathway for nonalcoholic fatty liver disease in an integrated US healthcare system demonstrates support of weight management and improved ALT.对美国一个综合医疗保健系统中针对非酒精性脂肪性肝病的专门护理路径进行的回顾性分析表明,体重管理得到了支持,丙氨酸转氨酶(ALT)水平有所改善。
BMC Gastroenterol. 2020 Oct 31;20(1):362. doi: 10.1186/s12876-020-01492-9.
4
AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.AGA 临床实践更新:非侵入性生物标志物在非酒精性脂肪性肝病评估和管理中的作用:专家综述。
Gastroenterology. 2023 Oct;165(4):1080-1088. doi: 10.1053/j.gastro.2023.06.013. Epub 2023 Aug 4.
5
Evaluation of a primary to secondary care referral pathway and novel nurse-led one-stop clinic for patients with suspected non-alcoholic fatty liver disease.对疑似非酒精性脂肪性肝病患者的初级保健至二级保健转诊途径及新型护士主导一站式诊所的评估。
Frontline Gastroenterol. 2020 Apr 7;12(2):102-107. doi: 10.1136/flgastro-2019-101304. eCollection 2021.
6
Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.意大利和加拿大艾滋病毒感染高危非酒精性脂肪性肝病老年患者肝纤维化的诊断:两步法评估。
Lancet HIV. 2022 Mar;9 Suppl 1:S4. doi: 10.1016/S2352-3018(22)00069-8.
7
Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.在初级保健中使用病例识别途径对非酒精性脂肪性肝病患者进行风险分层:一项横断面研究。
CMAJ Open. 2020 May 15;8(2):E370-E376. doi: 10.9778/cmajo.20200009. Print 2020 Apr-Jun.
8
Comparison of Pathway Referrals for Liver Fibrosis Risk Stratification Performed in Diabetology and Nutrition Clinics.糖尿病学和营养诊所中用于肝纤维化风险分层的通路转诊比较。
Diabetes Metab Syndr Obes. 2023 Jun 8;16:1721-1729. doi: 10.2147/DMSO.S407511. eCollection 2023.
9
Liver Stiffness Measurement by Using Transient Elastography in Bangladeshi Patients with Type 2 Diabetes Mellitus and Ultrasonography-Diagnosed Nonalcoholic Fatty Liver Disease.在孟加拉国2型糖尿病患者及超声诊断的非酒精性脂肪性肝病患者中使用瞬时弹性成像技术测量肝脏硬度
Diabetes Metab Syndr Obes. 2021 Jul 6;14:3089-3096. doi: 10.2147/DMSO.S317876. eCollection 2021.
10
Liver stiffness assessed by transient elastography as a potential indicator of chronic kidney disease in patients with nonalcoholic fatty liver disease.通过瞬时弹性成像评估的肝脏硬度作为非酒精性脂肪性肝病患者慢性肾病的潜在指标。
J Clin Lab Anal. 2019 Feb;33(2):e22657. doi: 10.1002/jcla.22657. Epub 2018 Sep 21.

引用本文的文献

1
Evaluating the Diagnostic Potential of the FIB-4 Index for Cystic Fibrosis-Associated Liver Disease in Adults: A Comparison with Transient Elastography.评估FIB-4指数对成人囊性纤维化相关肝病的诊断潜力:与瞬时弹性成像的比较。
J Clin Med. 2025 Jul 31;14(15):5404. doi: 10.3390/jcm14155404.
2
Detection of early-stage hepatocellular carcinoma: a retrospective evaluation of ultrasonography surveillance and surveillance adherence.早期肝细胞癌的检测:超声监测及监测依从性的回顾性评估
Transl Gastroenterol Hepatol. 2025 Jun 11;10:46. doi: 10.21037/tgh-24-119. eCollection 2025.
3
Evidence-based criteria for identifying at-risk individuals requiring liver disease screening.

本文引用的文献

1
Development and validation of diagnostic triage criteria for liver disease from a minimum data set enabling the 'intelligent LFT' pathway for the automated assessment of deranged liver enzymes.基于最小数据集开发和验证肝病诊断分诊标准,以实现用于自动评估肝功能异常酶的“智能肝功能检测”途径。
Frontline Gastroenterol. 2018 Jul;9(3):175-182. doi: 10.1136/flgastro-2017-100909. Epub 2018 Feb 7.
2
Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography.肥胖和 2 型糖尿病是一般实践中未确诊肝硬化的重要潜在危险因素:使用瞬时弹性成像的横断面研究。
Aliment Pharmacol Ther. 2018 Feb;47(4):504-515. doi: 10.1111/apt.14463. Epub 2017 Dec 6.
3
用于识别需要进行肝病筛查的高危个体的循证标准。
Hepatol Commun. 2025 Mar 21;9(4). doi: 10.1097/HC9.0000000000000679. eCollection 2025 Apr 1.
4
Screening high-risk Veterans for cirrhosis: taking a stepwise population health approach.对高危退伍军人进行肝硬化筛查:采取循序渐进的人群健康方法。
BMC Health Serv Res. 2025 Jan 29;25(1):168. doi: 10.1186/s12913-025-12216-8.
5
Comparison of models to predict incident chronic liver disease: a systematic review and external validation in Chinese adults.预测新发慢性肝病模型的比较:一项针对中国成年人的系统评价与外部验证
BMC Med. 2024 Dec 31;22(1):601. doi: 10.1186/s12916-024-03754-9.
6
Correspondence to editorial on "Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis".致关于“普通人群中具有临床意义的肝纤维化患病率:一项系统评价和荟萃分析”的社论的信函。
Clin Mol Hepatol. 2025 Jan;31(1):e48-e51. doi: 10.3350/cmh.2024.0777. Epub 2024 Sep 11.
7
Screening patients in general practice for advanced chronic liver disease using an innovative IT solution: The Liver Toolkit.使用创新的 IT 解决方案在全科医疗中筛查慢性肝病进展患者:Liver Toolkit。
Hepatol Commun. 2024 Jun 27;8(7). doi: 10.1097/HC9.0000000000000482. eCollection 2024 Jul 1.
8
Non-invasive tests for alcohol-associated liver disease.酒精性肝病的非侵入性检测
Hepatology. 2024 Dec 1;80(6):1390-1407. doi: 10.1097/HEP.0000000000000885. Epub 2024 Apr 12.
9
Screening for liver fibrosis: lessons from colorectal and lung cancer screening.肝纤维化筛查:来自结直肠癌和肺癌筛查的经验教训。
Nat Rev Gastroenterol Hepatol. 2024 Jul;21(7):517-527. doi: 10.1038/s41575-024-00907-2. Epub 2024 Mar 13.
10
FIB-4 and APRI for cirrhosis detection in a privately insured national cohort.利用FIB-4和APRI在一个拥有私人保险的全国队列中检测肝硬化
JHEP Rep. 2023 Sep 30;6(1):100925. doi: 10.1016/j.jhepr.2023.100925. eCollection 2024 Jan.
Guidelines on the management of abnormal liver blood tests.肝脏血液检查异常的管理指南。
Gut. 2018 Jan;67(1):6-19. doi: 10.1136/gutjnl-2017-314924. Epub 2017 Nov 9.
4
Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study.基于社区的非酒精性脂肪性肝病成人分层诊断途径的经济学评估:一项基于可行性研究的马尔可夫模型
BMJ Open. 2017 Jul 5;7(6):e015659. doi: 10.1136/bmjopen-2016-015659.
5
Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.一般人群中用非侵入性肝纤维化标志物定义的临床显著肝脏疾病的流行情况:系统评价。
Lancet Gastroenterol Hepatol. 2017 Apr;2(4):288-297. doi: 10.1016/S2468-1253(16)30205-9. Epub 2017 Feb 1.
6
Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.门静脉高压领域共识的拓展:巴韦诺VI共识研讨会报告:门静脉高压风险分层与个体化治疗
J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022. Epub 2015 Jun 3.
7
Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography.直接针对风险因素进行筛查可显著提高基层医疗中肝硬化的检出率:一项利用瞬时弹性成像的横断面诊断研究。
BMJ Open. 2015 May 3;5(4):e007516. doi: 10.1136/bmjopen-2014-007516.
8
Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis.应对英国的肝脏疾病:实现卓越医疗保健以及降低因过量饮酒、肥胖和病毒性肝炎等生活方式问题导致过早死亡的蓝图。
Lancet. 2014 Nov 29;384(9958):1953-97. doi: 10.1016/S0140-6736(14)61838-9.
9
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.简单的非侵入性纤维化评分系统可以可靠地排除非酒精性脂肪性肝病患者的晚期纤维化。
Gut. 2010 Sep;59(9):1265-9. doi: 10.1136/gut.2010.216077.
10
Health outcomes following liver function testing in primary care: a retrospective cohort study.基层医疗中肝功能检测后的健康结局:一项回顾性队列研究。
Fam Pract. 2009 Aug;26(4):251-9. doi: 10.1093/fampra/cmp025. Epub 2009 May 12.